Keywords: Astellas, OSI Pharmaceuticals, M&A, Tarceva, Oncology, Urology, Immunology

Astellas goes hostile, offering a 40% premium to buy OSI Pharma for $3.5 billion

Article | 01 March 2010

Print This

Despite previous rejections of its advances, Japanese drug major Astellas Pharma this morning said it plans to acquire USA-based OSI ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in